Will the future of pharmacovigilance be more automated?-Reference-Cited by-同舟云学术

Will the future of pharmacovigilance be more automated?

Published:2023-07-03 Issue:7 Volume:22 Page:541-548
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Salvo Francesco¹²^ORCID,Micallef Joelle³,Lahouegue Amir⁴,Chouchana Laurent⁵^ORCID,Létinier Louis¹²⁶,Faillie Jean-Luc⁷,Pariente Antoine¹²^ORCID

Affiliation:

1. University of Bordeaux, Inserm, BPH, Team AHeaD, Bordeaux, France

2. CHU de Bordeaux, Service de Pharmacologie Medicale, Bordeaux, France

3. Pharmacovigilance Centre, Department of Clinical Pharmacology and Pharmacovigilance, University of Aix Marseille, INSERM UMR 1106 Institut de Neurosciences des Systèmes, Marseille, France

4. Department of Pharmacovigilance and Medical Information, Astrazeneca, Courbevoie, France

5. Regional Center of Pharmacovigilance, Pharmacology Department, Cochin Port Royal University Hospital, Paris, France

6. Synapse Medicine, Bordeaux, France

7. Inserm, Departement de Pharmacologie Medicale Et Toxicologie, Centre Regional de PV, Institut Desbrest D’epidemiologie Et de Sante Publique, CHU de Montpellier, Universite Montpellier, Montpellier, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2227091

Reference50 articles.

1. EMA. Good pharmacovigilance practices; 2018. [cited Mar 17, 2023]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices

2. US FDA. Good pharmacovigilance practices and pharmacoepidemiologic assessment. [cited Mar 17, 2023]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment

3. Desogestrel and panic attacks - a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports

4. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?

5. Under-reporting of adverse drug reactions in general practice